Fluzone High-Dose

Fluzone High-Dose is a high-dose quadrivalent inactivated influenza vaccine (HD-QIV) manufactured by Sanofi Pasteur. It is a split-virus biologic vaccine that contains 60 µg of hemagglutinin antigen from each of four influenza strains (two A and two B), which is four times the amount found in standard-dose vaccines. The vaccine is designed to improve immune protection in populations that typically exhibit suboptimal responses to standard vaccination, such as older adults and immunocompromised individuals. In clinical research led by Vanderbilt University Medical Center, it is being evaluated in lung transplant recipients to determine if the higher antigen concentration improves immunogenicity and safety compared to standard-dose vaccines in the context of chronic immunosuppression.

Brand names

Fluzone High-DoseFluzone High-Dose Quadrivalent

Other names

HD-IIVHD-QIVFluzone HDFluzone High-Dose Inactivated Influenza VaccineFluzone High-Dose Inactivated Influenza Vaccine-Vanderbilt University Medical Center-influenza